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ImagingNano- and microparticles have increasingly widespread applications in nanomedicine, ranging from drug
delivery to imaging. Poly(lactic-co-glycolic acid) (PLGA) particles are the most widely-applied type of par-
ticles due to their biocompatibility and biodegradability. Here, we discuss the preparation of PLGA par-
ticles, and various modifications to tailor particles for applications in biological systems. We highlight
new preparation approaches, including microfluidics and PRINT method, and modifications of PLGA par-
ticles resulting in novel or responsive properties, such as Janus or upconversion particles. Finally, we
describe how the preparation methods can- and should-be adapted to tailor the properties of particles
for the desired biomedical application. Our aim is to enable researchers who work with PLGA particles
to better appreciate the effects of the selected preparation procedure on the final properties of the par-
ticles and its biological implications.
Statement of Significance
Nanoparticles are increasingly important in the field of biomedicine. Particles made of polymers are in
the spotlight, due to their biodegradability, biocompatibility, versatility. In this review, we aim to discuss
the range of formulation techniques, manipulations, and applications of poly(lactic-co-glycolic acid)
(PLGA) particles, to enable a researcher to effectively select or design the optimal particles for their appli-
cation. We describe the various techniques of PLGA particle synthesis and their impact on possible appli-
cations. We focus on recent developments in the field of PLGA particles, and new synthesis techniques
that have emerged over the past years. Overall, we show how the chemistry of PLGA particles can be
adapted to solve pressing biological needs.
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The past decades have seen rapid development in the fields of
nanotechnology and nanomedicine. Nanomedicine – a subset of
nanotechnology – is described as the monitoring, repair, construc-
tion, and control of human biological systems at the molecular
level, using engineered nanodevices and nanostructures [1]. To
be used in medicine, nanomaterials must have specific characteris-
tics, such as a high surface-area-to-volume ratio, biocompatibility,
and control of biodistribution and circulatory half-life. Further-
more, nanoparticles can be designed in different shapes and sizes
and their surface can be modified to fulfill their biological need.
Polymer-based particles are now frequently studied and used as
drug carriers in cancer and other pathologic conditions, as control-
ling their synthesis enables customizing their physicochemical
properties. Thus, size distribution or side-chain composition of
the polymer can be modified to improve delivery efficiency [2].
The ‘‘ideal” polymer for such particles must be biodegradable, with
toxicologically safe in vivo degradation products, which can be
easily eliminated by the metabolic pathways. Among various poly-
mers, poly(lactic-co-glycolic acid) (PLGA) has received the highest
attention because of its favorable degradation characteristics and
biocompatibility. The application of PLGA as a biomaterial dates
back to the 1970s, when it was developed as a material for
biodegradable sutures, followed by its use in the production of
devices such as implants, tissue grafts, prosthetic devices, and
therapeutic devices. Now the technology has matured to the
nanoscale. PLGA has been used for the encapsulation of various
types of drugs, such as paclitaxel, doxorubicin, cisplatin, docetaxel,
and curcumin [3]. Table 1 presents drug encapsulation where PLGA
is used to control release, along with the encapsulation method
used.hows examples of drugs, which are encapsulated in PLGA.
Product Application
eotide acetate Sandostatin LAR Depot acromegaly, severe diarrhea, sudden r
of the face and neck caused by carcin
tumors
rolide acetate Lupron Depot advanced prostate cancer, endometri
uterine fibroids,
relin acetate Suprecur MP (Japan) endometriosis, uterine myoma
omycin Vancocin HCl Pulvules bacterial infections
obarbital Solfoton partial and generalized tonic-clonic s
epilepsy
rbitacin I N/A inhibitor of STAT3/JAK2 signaling
osporin A Gengraf, Neoral organ transplantation for immune su
roic acid Depakene, Depacon seizures disorders, manic disordersPLGA particles offer a number of advantages for biomedical
applications: they can be targeted in vivo using antibodies, they
protect DNA and other biomolecules from degradation, or, when
modified with targeting ligands, they effectively enhance immune
response [4]. Finally, aiming at clinical use, they can be stored for
lengthy periods in a powder form. Current approved PLGA particles
include, for example, Lupron Depot (Abbott Laboratories, USA)
and Trelstar (Watson Pharmaceuticals, USA) for sustained release
of leuprolide and triptorelin respectively, as well as several other
formulations reviewed elsewhere [5–7]. PLGA has been used as a
suture material since 1974 under the product name Vicryl (Ethi-
con Inc, USA), a 10:90 PLGA braided construct (http://www.ethi-
con.com/). Other examples of currently available PLGA sutures
include Polyglactin 910 (Dolphin Sutures, Futura Surgicare Pvt
Ltd, India) or Polysorb (Syneture, USA). Additionally, there are
several ongoing and recently completed clinical trials involving
the use of PLGA as bioscaffolds, biodegradable polymer stents or
bioabsorbable screws (https://clinicaltrials.gov/ct2/results?term=
PLGA&Search=Search).
The properties of PLGA particles are strongly dependent on the
preparation method. Specific applications, e.g. cell targeting, imag-
ing, and therapeutic delivery, require particles with well-defined
physicochemical properties. Due to its popularity, there have been
several reviews published focusing on the formulation of PLGA
particles. Sah et al. describe different well-established formulation
techniques for PLGA particles and how to improve drug encapsula-
tion efficiency [8]. In another review, Sharma et al. address the
issues related to PLGA-based nanoparticles, like methods of prepa-
ration, characterization techniques, surface modification, and
mechanism of drug release, as well as the drawbacks of using PLGA
nanoparticles as drug delivery systems [9]. In this review, we high-




osis, hydrophilic w/o/w emulsion solvent evaporation [134]
hydrophilic spray-drying [134]
hydrophilic nanoprecipitation-solvent evaporation [135]
eizures, hydrophilic nanoprecipitation-solvent evaporation [135]
hydrophobic nanoprecipitation-solvent evaporation [136]
ppression hydrophobic nanoprecipitation-solvent evaporation [135]
hydrophobic nanoprecipitation-solvent evaporation [135]
40 E. Swider et al. / Acta Biomaterialia 73 (2018) 38–51the design of PLGA particles, along with relevant modifications
necessary. We emphasize both novel fabrication techniques, such
as microfluidics or inkjet printing, and modifications of the PLGA
polymer resulting in materials with smart properties, e.g. Janus
nanoparticles, thermo- or pH-responsive particles, and upconver-
sion nanoparticles. Finally, we discuss how the recent develop-
ments of PLGA particles can be applied in modern nanomedicine
to improve the outcome of the treatment. For clarity, here we refer
to particles under 1000 nm as nanoparticles, as those are often pre-
sented as nanoparticles in the literature, while larger particles are
referred to as microparticles.Fig. 1. The release profile from PLGA implants. Figure represents modeled in vivo
release profiles of risperidone drug for 50:50, 65:35, 75:25 and 85:15 PLGA, where
the first number represents the amount of lactic acid and second number the
amount of glycolic acid (e.g. 85:15 means 85% lactic and 15% glycolic acid) [132].
Copyright (2010) Pharmaceutical Research.2. Physicochemical properties of PLGA
PLGA is a linear copolymer with lactic and glycolic acid repeat
units, which can be organized as a block-co-polymer or statistical
polymer (Scheme 1). The body can easily metabolize both mono-
mers into carbon dioxide and water via the tricarboxylic acid cycle,
resulting in minimal systemic toxicity [10]. PLGA can be synthe-
sized by direct polycondensation of lactic and glycolic acid, which
usually results in copolymers with a low molecular weight and
broad molar mass distribution. Polymers with higher molecular
weight and narrower molar mass distribution can be obtained by
the ring-opening polymerization of cyclic dimers [11]. In general,
the molecular weight of PLGA can be adjusted from 4 to 240 kDa
by changing the polymerization conditions and the ratio of mono-
mer to initiator [10]. The biodegradation rate of PLGA depends on
several factors, e.g. the composition of the polymer [12] and its
microstructure [13]. The degradation of PLGA is faster for polymers
with the increased amount of glycolic acid units [12,14]. Polymers
with a 50:50 ratio of lactic and glycolic acids have the fastest
degradation rate and are therefore one of the most frequently used
polymers in nanomedicine [12]. PLGA with the 50:50 ratio has the
degradation rate of around two months in vivo and has the fastest
release rate when compared to other ratios (Fig. 1) [10].
PLGA can be dissolved in a range of common organic solvents,
depending on its composition. PLGA with a higher amount of lactic
acid is dissolved by chlorinated solvents, such as dichloromethane
or chloroform, and by water-miscible solvents, like acetone or
tetrahydrofuran, while PLGA with a higher amount of glycolic acid
is dissolved by fluorinated solvents, like hexafluoroisopropanol
[15,16]. Finally, the glass transition temperature of PLGA can also
be exploited; typically PLGA undergoes glass transition above body
temperature, between 40 and 60 C and this decreases with a
decrease in the molecular weight and decrease of PLA content in
the copolymer [10].
The physicochemical properties of PLGA particles primarily
depend on properties of PLGA polymer used for synthesis, includ-
ing the ratio of lactic acid to glycolic acid, molecular weight, and
storage temperature [10,15,17]. However, most of the particle
properties, for example, particle size and size distribution, are
strongly dependent on the synthesis method in general and influ-
enced by the synthesis parameters within the same method in par-
ticular, including the addition of encapsulated substance.Scheme 1. Hydrolysis of PLGA. PLGA hydrolysis leads to two monomers, lactic and glyc
acid cycle, resulting in minimal systemic toxicity.PLGA particles can be functionalized with poly(ethylene glycol)
(PEG) or other hydrophilic polymers resulting in particles with a
‘‘stealth” surface. These stealth particles become almost invisible
to the reticulo-endothelial system, which is responsible for the
clearance of particles from the blood stream, and have longer cir-
culation (Table 2) [18,19]. Furthermore, the addition of coating
materials may improve the production of particles with well-
controlled and reproducible sustained-release profiles [20]. PEG
is a water-soluble, non-ionic polymer, which has become a gold
standard for the stealth modification of nanoparticles to increase
their blood circulation time [21]. PEG has good synthesis flexibility
and its end groups can be easily modified [21]. The addition of PEG
layer can enhance particle hydrophilicity [15], resulting in reduced
interactions with biomolecules, e.g. lipids or serum proteins, and
therefore protect particles from elimination from the blood stream
through the RES [22].
Some of the other commonly used surface-coating materials
include PEG-containing block-co-polymers such as poloxamer or
poloxamine, polysorbate 80 (TWEEN-80) [23,24]. Poloxamer is
(Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly
(ethylene glycol)) block-co-polymer. Poloxamer is a coating mate-
rial, which can enhance proapoptotic signaling and it can preferen-
tially target cancer cells [25]. This coating material can be used
during the encapsulation of hydrophobic drugs. Nevertheless, high
doses of poloxamer can induce hyperlipidemia and hypercholes-
terolemia [25]. Poloxamine is an amphiphilic block-co-polymer
formed by four arms of poly(ethylene oxide)-poly(propylene
oxide) blocks, and it is useful in solubilization and stabilization
of hydrophobic drugs, and it prolongs blood circulation half-life
[26]. Polysorbate 80 is useful in improving the transport of drugs
across the blood-brain barrier, however, it may cause severe non-
immunologic anaphylactoid reactions [27]. Further advantages
and downsides of these coating materials are described in Table 2.
Besides the modification of the particle surface, the PLGA poly-
mer itself can be further modified by the linkage of PEG chains
prior to particle synthesis, to form di-, tri-block copolymers [28].olic acid- both familiar cell metabolites. These are metabolized via the tricarboxylic
Table 2
Overview of materials used for coating the PLGA particles, with examples from the literature.
Coating material Advantages Disadvantages Ref.



























E. Swider et al. / Acta Biomaterialia 73 (2018) 38–51 41When formulating the particles from PEG-PLGA copolymer, PEG
chains align themselves in the direction of external aqueous phase.
Triblock copolymers can be arranged in an ABA (PLGA-PEG-PLGA)
or BAB (PEG-PLGA-PEG) manner, where the different blocks are
coupled to each other via an ester linkage. There have been several
studies using PEG-PLGA nanoparticles for various applications,
with different methods for particle synthesis [29–31]. e.g.
methoxy-PEG-PLGA (mPEG-PLGA) which was used to form core-
shell nanoparticles via double emulsification for co-delivery of
hydrophilic and hydrophobic drugs [32].
While PEGylation can shield nanoparticles from being recog-
nized by the immune system, there have been reports, which sug-
gest the formation of PEG-specific antibodies after the
administration of PEG-coated liposomes [33]. The formation of such
antibodies results not only in the early clearance of PEGylated par-
ticles from blood (Accelerated Blood Clearance or ABC effect) [34],
but can also contribute to the change in pharmacokinetic profile of
subsequent injected doses of the PEGylated compound.Other disad-
vantages of PEGylation include the degradation of PEG leading to
production of toxic peroxides or the accumulation of PEG in organs
by vacuolization [34,35]. This issue needs to be taken into account
when considering the safety of nanoparticle-based therapeutics.Scheme 2. Aspects needed for the design of particles. Particle fabrication should be pl
parameters, can be selected and optimized for an appropriate end product.3. Preparation methods of PLGA nano- and microparticles
There are several methods of particle preparation from PLGA
copolymers. To prepare particles with controlled properties, such
as size or degradation rate, it is important to choose not only the
right method, but also the right materials and synthesis parame-
ters. For example, particle size can be affected by the amount of
surfactant [36], polymer concentration, encapsulated compound,
and the type and extent of energy input (e.g. sonication, homoge-
nization or shear stirring) (Scheme 2).
The choice of preparation method is also important for the load-
ing and release efficiency of any entrapped agents, which depends
on both the specific properties of the agent and the eventual route
of delivery of the particles. Furthermore, the preparation of parti-
cles of the desired size, surface charge, encapsulation efficiency,
and release characteristics, requires precise control of specific
parameters [23].
Before describing the new methods, we provide a brief sum-
mary of established techniques, with the key characteristics of
obtained particles presented in Table 3 and Fig. 2. However, for
more detailed information on the last, we highly recommend a
review by Astete et al. [37].anned with the final application in mind. Several techniques, with many variable
Table 3
Overview of PLGA particles synthesis methods.
Method Diameter range Mixing method Solvent Surfactant Disadvantages Advantages Ref.
Double-emulsion solvent-
evaporation






















size affected by cargo













size affected by polymer
concentration
low energy consumption
no high share forces
[5,40–42]








diversity in particle shape
















minimizes stress to protein
cargo
good for heat sensitive
substances
[47–51]







slow diffusive mixing monodisperse droplets [54,56–58,141]
Membrane extrusion
emulsification







































Fig. 2. Graphical representation of different preparation techniques of PLGA particles. PLGA particles can be formulated using various methods, including (A) single emulsion-
solvent evaporation (B) encapsulation of a protein into PLGA nanoparticles using double emulsion solvent evaporation (C) spray-drying (D) nanoprecipitation (E)
microfluidics, and (F) membrane extrusion emulsification. (w – water, w/o – water-in-oil, w/o/w – water-in-oil-in-water, PVA-polyvinyl alcohol). Scanning electron
microscopy images represent particles prepared using: (G) emulsion solvent-evaporation–scale bar 1 mm [123] (Copyright (2010) Elsevier, Ltd.) (H) spray-drying [43]
(Copyright (2014) Springer) (I) microfluidics [55] (Copyright (2009) John Wiley and Sons) (J) PRINT technique–particles of different shapes [70] (Copyright (2011) ACS
Publications) (K) Janus particles made using a microfluidic system [89] (Published by The Royal Society of Chemistry (2015)).
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3.1.1. Single and double emulsion–solvent evaporation method
Standard emulsification methods are based on the preparation
of an oil-in-water (o/w) or water-in-oil-in-water (w/o/w) emulsion
and are well-suited to encapsulate different types of lipophilic and
hydrophilic drugs [38]. The emulsion consists of an oil phase with
PLGA and the lipophilic agent (e.g. drug) in a non-polar organic sol-
vent, and an aqueous phase with a surfactant. The organic phase is
added to the aqueous phase under sonication or homogenization,
followed by solvent evaporation and collection of particles
(Fig. 2A,B) [39]. The final product is freeze-dried and can attain a
shelf-life of several years. The single and double emulsion tech-
nique can be simply scaled up by adjusting the amount of polymer,
type of solvents, addition of drugs, type of surfactant and sonica-
tion or homogenization [37]. The single-emulsion method is suit-
able for the encapsulation of hydrophobic compounds, while the
double-emulsion method is used to encapsulate more hydrophilic
cargo [38]. Both methods use high shear stress, which can be dis-
advantageous for the encapsulation of more fragile compounds,
such as proteins.3.1.2. Nanoprecipitation
Nanoprecipitation is especially useful for the synthesis of
nanoparticles with size below 100 nm [5,40–42]. Here, polymer
and drug are dissolved in a polar, water-miscible solvent and
added in a controlled manner using an auto-injector, to an aqueous
phase (Fig. 2D). Nanoprecipitation is typically used for the encap-
sulation of hydrophobic drugs, since the loading efficiency for
hydrophilic compounds is low due to their poor interaction withthe PLGA. This poor interaction leads to the diffusion of the hydro-
philic drug during the solvent diffusion from the organic to aque-
ous phase [40]. Another disadvantage of this method is that
nanoparticle size is affected by the polymer concentration, where
lower polymer concentration results in smaller particles [37].
3.1.3. Spray-drying
Spray-drying is a rapid method with only a few processing
parameters. It can be used to encapsulate both hydrophilic and
lipophilic drugs, peptides, and proteins into a particle. Particles
are prepared by spraying solid-in-oil (s/o) dispersion or w/o emul-
sion in a stream of heated air (Fig. 2C). Fig. 2H shows scanning elec-
tron microscopy (SEM) images of particles produced with the
spray-drying method. The selection between s/o and w/o method
depends on the properties of the encapsulated agents, particularly
their hydrophilicity or hydrophobicity [43–45]. The main draw-
back of the conventional spray-drying approach is a significant loss
of product caused by the agglomeration of particles or their adhe-
sion to the walls of the spray-drying apparatus, which can be
resolved with the use of an anti-adherent [46].
3.1.4. Emulsification/salting-out
The salting-out method is based on the separation of an aque-
ous phase from an organic phase via the addition of suitable elec-
trolytes [47]. Particles form through controlled dilution of the
electrolyte content, as the solvent diffuses from the organic dro-
plets. Salting out is a robust technique, where size is not highly
sensitive to increase in polymer concentration. Since the salting
out agent is water soluble, this method is suitable for hydrophobic
compounds. Downsides of the salting-out technique include low
44 E. Swider et al. / Acta Biomaterialia 73 (2018) 38–51yield, poor entrapment efficiency, and a high polydispersity index
(PDI) [48–51]. However, the method is useful for the processing
of heat sensitive substances and can easily be scaled up [47].3.2. New design methods for PLGA particles
Conventional methods of particle synthesis frequently result in
particles with a broad size distribution, leading to problems with
control over reproducibility, biodistribution, drug loading, and
encapsulation efficiency. Other issues facing current fabrication
techniques for PLGA particles include a poor ability to tailor release
kinetics and to co-deliver dual drugs with different solubility prop-
erties [52]. Recent developments in the formulation methods
addressing these issues are described in the following sections.Fig. 3. Schematic view of droplet-based microfluidic geometries: (A) The T-junction
geometry, the horizontal flow of the aqueous phase is sheared by oil and thereby
generates droplets. (B) In the flow-focusing geometry, droplets are produced by
shearing the aqueous stream from two directions. (C) The co-flow geometry, here
the aqueous phase is forced through a capillary, which is placed coaxially inside a
bigger capillary, through which an immiscible oil is pumped [133]. Published by
The Royal Society of Chemistry (2016).3.2.1. Microfluidic platforms
Microfluidics is a new field which deals with the manipulation
of fluids at the micro- and nanoscale. A classic microfluidic device
includes a network of microchannels which are molded into a
material forming a microfluidic-chip, inlets to inject fluids, microp-
umps and microvalves to manipulate fluids within the chip, outlets
to remove fluids, and a detection system for analysis [53].
Microfluidic chips can be built using materials, such as glass, sili-
cone or polymer (e.g. poly(dimethylsiloxane) (PDMS)), and formed
into different geometries to control the droplet formation [54,55].
Microfluidics has different applications, one of them is a develop-
ment of emulsions via droplet-based microfluidic systems.
Droplet-based microfluidic systems provide a new route to pro-
duce monodisperse and uniform droplet emulsions in a controlled
way, with the use of various materials and reagents (Fig. 2E,I) [56–
58]. For example, glass capillary devices consist of a set of glass
capillaries which are chemically resistant and their geometry
allows for controlled synthesis of multiple emulsions [59]. A major
disadvantage of glass capillary devices is in upscaling production,
as it is difficult to reproducibly construct more than one device
at a time and have many identical devices [54]. A solution to this
problem could be the use of PDMS microfluidic device. Here, a chip
is built from PDMS bonded to a thin glass slide, which can also
allow visualization of the sample and monitoring of the concentra-
tion of a drug at the same time [60]. These devices can be repli-
cated and produced in big numbers, making them suitable for
large-scale synthesis [54]. However, PDMS is less chemically inert,
might become swollen with some solvents, and it can absorb small
molecules, like biomolecules or drugs.
The formulation of droplets can be controlled by either passive
or active techniques. In both active and passive mixing, the droplet
diameter can be controlled by controlling the flow rates of the con-
tinuous and dispersed phases, the ratio between these liquid
phases, and the geometries of the system [61]. In passive mixing,
the mixing of organic and aqueous phases is affected only by the
flow rate and the geometry of the microfluidic chip and thus no
additional ‘‘active” energy input is present [62]. In active droplet
production, the droplet diameter can be further tuned by addi-
tional energy input in the mixing part of the device by moving wall
structures, integrating microheaters, and magnetically or pneu-
matically driven microvalves [62].
The most common geometries used for the formation of dro-
plets are a T-shaped junction, a flow focusing (FF) system, and
co-flowing streams (Fig. 3). T-junction geometry is the simplest
geometry for producing and manipulating droplets. This type of
geometry combines a horizontal and a perpendicular channel,
resembling the two branches of a ‘‘T” [63]. During the droplet gen-
eration with T-junction, the continuous phase flows through the
horizontal channel, while the dispersed phase comes through a
channel perpendicular to it [64].In the FF geometry, the dispersed phase flows inside the square
capillary and the continuous phase flows from the two side chan-
nels. The dispersed phase is focused by the continuous phase
through the narrow opening of the tapered round capillary, leading
to the formation of emulsions in the collection capillary. Despite
the diversity of the structures in the FF configuration, the mecha-
nisms of droplet formation are similar to the T-junction configura-
tion [63]. The set-up of the FF geometry uses symmetric shearing
force by the continuous phase, resulting in a more stable and con-
trollable formation of droplets [63]. Therefore, the FF system can
be used for the production of smaller droplets, even if the opening
of the channel has a larger size [62]. In the co-flow system, the dis-
persed phase flows inside the round capillary, while the continu-
ous phase flows between the square and round capillaries. Here,
both fluid phases flow in the same direction. These systems are
used to form single emulsions [54]. To produce double emulsions
a combination of FF and co-flow geometries can be used [54].
There are several distinct regimes of droplet formation in the
geometries described above, e.g. dripping, squeezing, and jetting.
The type of regime influences the size of generated droplets. For
example, in the squeezing regime the size of droplet is described
as a function of the ratio of the flow rates of the two liquid phases.
Further details of different regimes have been described elsewhere
[62].
The major advantage of a microfluidic platform is that it allows
the selection of the chemical composition and structure of the par-
ticles needed for specific application [60]. With the microfluidic
system, the physicochemical parameters of particles can be easily
adjusted by the type of solvent and non-solvent, the solubility
and type of encapsulated cargo, the concentrations of surfactant
and polymer, and the presence of additional co-surfactant mole-
cules [65]. In Table 3 we list further details about microfluidic sys-
tems regarding the size of particles produced and commonly used
solvents.
Fig. 4. Figure represents the released amount of PDADMAC per surface area in
dependence of the pH [77]. Copyright (2015) Beilstein Journal of Nanotechnology.
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The membrane extrusion emulsification method forms emul-
sions with a narrow size distribution using membranes with
defined pore sizes to form droplets from 200 nm up to 1–5 mm in
size. Commonly used membranes include polycarbonate and poly
(tetrafluoroethylene), and Shirasu Porous Glass (SPG Technology
Co. Ltd, Japan), although some other materials have also been stud-
ied [66]. Polycarbonate membranes are thin and, thus, they need to
be additionally supported with drain discs or nylon meshes in
order to protect the membrane from rupture. Polycarbonate mem-
branes can easily be sterilized and can be used as a disposable, thus
lowering any cross-contamination risk [67]. Generally, the mem-
brane extrusion emulsification method involves the synthesis of
single or double emulsion, which is further extruded through the
membrane using high pressure (Fig. 2F) [66,68]. A major advantage
of the membrane extrusion technique is that obtained particles are
more homogenous when compared to solvent-evaporation meth-
ods. The membrane extrusion emulsification is one of the tech-
niques, which allows the simultaneous encapsulation of
hydrophilic or lipophilic therapeutics and an imaging agent, such
as quantum dots, leading to the formation of multifunctional par-
ticles [69].
3.2.3. PRINT technique
The group of DeSimone described a novel Particle Replication In
Nonwetting Templates (PRINT) technique for the synthesis of
micro- and nanoparticles [70]. This method uses a mold made of
a fluoropolymer to make the particles. The use of different tem-
plates for the production of these molds results in cavities with dif-
ferent shapes, for example, cubic particles used for the
encapsulation of doxorubicin [70]. These cavities are then filled
with PLGA solution. After solidification, the particles can be
removed with a harvesting film. This technique allows for the pro-
duction of particles in a size range of 10 nm to 200 mm (Table 2)
[71,72]. PRINT allows for the synthesis of particles with a specific
size and shape (Fig. 2J), as it has been shown that shape can have
an important effect on the biological responses to nanoparticles
[70]. Moreover, particles made using this technique can be loaded
with fluorophores, MRI contrast agents, and both hydrophilic and
hydrophobic chemotherapeutics. Along with the microfluidic plat-
form and membrane extrusion techniques, the PRINT technique
has an important advantage above other methods, as the resulting
particles are homogenous with a low PDI. This is highly beneficial
for applications, such as drug delivery, as monodisperse particles
provide more equal and predictable distribution of drugs.4. Smart PLGA based nanomaterials
Smart or stimuli-responsive polymeric systems can change
their properties depending on the environment they are placed
in. These systems can be sensitive to stimuli such as temperature,
light intensity, magnetic field or pH [73]. In this section, we
describe the modification of PLGA particles, which result in smart
nanocarriers.
4.1. pH-responsive particles
Typical release profiles of PLGA particles consist of an initial
burst phase, induction period, slow release phase, and a final
release phase. One of the recent approaches to modify this release
profile is the development of the pH-responsive particles. These
particles contain a pH-responsive polymer in addition to PLGA.
This type of particle will release their cargo only when the opti-
mum pH window is reached [74], either in a specific organ, intra-
cellular compartment, tumor microenvironment or inflammation[75]. There are several ways of developing pH-responsive particles,
e.g. b-amino ester linkages within a polymer give pH sensitivity
and make the polymer core soluble in water. Particles can be also
designed to release their payload intracellularly. This release is
achieved, for example, through the conjugation of a drug to the
polymer backbone via an acid–responsive hydrazine bond or via
a disulfide linker [76]. pH-sensitive particles can be also developed
using the layer-by layer self-assembly technique, with poly(acrylic
acid) as a pH-sensitive component and poly(diallyldimethylammo-
nium chloride) (PDADMAC) as the releasable polycation [77].
Above modifications can also influence the release of encapsulated
cargo as presented in Fig. 4. Furthermore, such modifications can
trigger the release of drug within solid tumors, as they take advan-
tage of tumor’s acidic environment.4.2. Thermo-sensitive particles
Another group of stimuli-responsive materials show Upper or
Lower Critical Solution Temperature (UCST or LCST). Such materi-
als are soluble in aqueous solution only above or below the critical
temperature. Changes in temperature are relatively easy to control
in both in vitro and in vivo settings, allowing the application of
thermo-sensitive materials for biomedical applications. Thermo-
sensitive nanocarriers should keep their load at body temperature
(37 C) and quickly deliver the therapeutic within a heated tar-
geted area (40–42 C). Such nanocarriers can also react and
release their cargo upon temperature decrease, e.g. during
cryotherapy [75]. Poly(N-isopropylacrylamide) (pNIPAm) is per-
haps the most intensively studied thermoresponsive polymer. PNi-
PAm undergoes the hydrophilic-hydrophobic phase transition at
31–32 C [78]. At temperatures below its LCST, pNiPAm nanopar-
ticles are swollen and hydrophilic, while with the increase in tem-
perature above the LCST they collapse as the polymer becomes
hydrophobic [78]. An example of thermo-sensitive particles that
use pNiPAm, are magnetic-based core-shell particles (MBCSPs),
which were designed to target skin cancer and deliver chemother-
apeutics in a controlled manner [79]. These particles have a
thermo-responsive shell of poly(N-isopropylacrylamide-acryla
mide-allylamine) and a core of PLGA embedded with magnetite
nanoparticles. To target melanoma cancer cells, these particles
were further conjugated with peptides that bind to specific recep-
tors on melanoma cells. MBCSPs allow multifunctional delivery of
therapeutics due to the degradation of PLGA core, controlled
release via the temperature changes, and receptor-mediated
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duce regions of hypointensity in magnetic resonance imaging
(MRI) [79]. Another example of the use of temperature-
responsive polymers describes the encapsulation of naltrexone, a
drug which stops the activity of opioids [80]. In their work, Salehi
et al. studied the preparation of thermosensitive terpolymer poly
(N-isopropylacrylamide-acrylamide-vinilpyrrolidone) and its
blend with PLGA. They showed that the addition of PLGA to ter-
polymer leads to a lower burst effect and slower release rate of nal-
trexone at 37 C [80].4.3. Light-responsive particles
Particles made out of light-sensitive polymer alter their proper-
ties when exposed to light. Light irradiation can be used to activate
the drug release from the polymeric carriers. This type of stimulus
is of special interest, as its intensity is precisely tuned, it can be
remotely used for a short period of time, and applied directly at
the site of interest. One of the ways to increase the light sensitivity
of polymers is the introduction of multiple light-sensitive trigger-
ing groups to the polymer chain [81]. The attachment of light-
responsive groups to cyclizing side chains leads to the formation
of polymers that can quickly degrade in response to UV light,
and release encapsulated cargo [82]. One typical example is
PLGA-based polymers containing pendant nucleophiles protected
with a photocleavable o-nitrobenzyl (ONB) group, which degrades
in response to UV light. Light irradiation makes the component
polymers more hydrophilic, allowing water to infiltrate the parti-
cles and thus foster hydrolysis of the polymer backbone [82].
Park et al. developed doxorubicin-loaded PLGA-gold half-shell
nanoparticles, where the gold films were placed on drug-loaded
nanoparticles [83]. This approach combines photo- and thermal
treatment. The gold surface absorbs light and converts it to cyto-
toxic heat, while the drug loaded into polymeric nanoparticles is
released. In this study, the group showed that drug loaded in PLGA
nanoparticles was released faster upon near-infrared (NIR) irradia-
tion, as PLGA is degraded more rapidly at higher temperatures [83].
Thus, there is a possibility of controlling drug release by adjusting
the intensity of NIR irradiation. However, when designing a light-
responsive system, one should keep in mind the limited penetra-
tion depth of external light in biological tissue. Such limitations
can be solved with the use of upconversion particles described in
the next section.4.4. Upconversion particles
Another system, which is used with the combination with light,
are uponversion particles. Upconversion particles have the ability
to convert NIR light (800, 915, 980 nm) to lower emission wave-
lengths at ultraviolet (UV), visible (VIS), or the NIR region by means
of a low-power continuous-wave diode laser [84]. This characteris-
tic is especially attractive, as NIR excitation permits deep tissue
penetration, while the UV and VIS light emitted by upconversion
particles allows for the photo-triggerable processes [85].
Upconversion particles can be created by the encapsulation of
the sensitizer, e.g. Yb(III), and activators, e.g. Gd(III), Tm(III), within
PLGA-PEG nanoparticles [85]. Such particles can further contain a
photosensitizer, e.g. protoporphyrin IX, which is activated upon
irradiation by absorbing UV or vis light, and results in the genera-
tion of reactive-oxygen species (ROS) [85]. The use of co-
encapsulation of upconversion particles with protoporphyrin IX
within PLGA-PEG lead to higher ROS production than when only
protoporphyrin IX was encapsulated alone [85].5. Janus particles
Janus particles are heterogenous particles consisting of two dis-
tinct hemispheres of different materials that bring different prop-
erties or functions to each hemisphere. Due to this characteristic,
Janus particles recently received a lot of attention [86]. The term
Janus is derived from the name of a two-headed god in ancient
Roman mythology, as Janus particles have a similar structure with
two distinct ‘‘heads” or hemispheres (Fig. 2K), making them suit-
able for many applications for which other types of particles are
not always suitable, such as the delivery of two different drugs
or the encapsulation of both a drug and an imaging agent
[87,88]. Janus particles can be formulated using e.g. a fluidic nano-
precipitation system [88] or a droplet-based microfluidic platform
[89]. In Janus particles, each side of the particle can be tailored for
specific needs, i.e. co-delivery of drugs with different solubility.
With the presence of both a hydrophilic and a hydrophobic sphere,
these particles can stabilize both o/w and w/o single emulsions.
Particles with two surfaces can be formulated using polymers with
different end-groups and additionally coated with various chemi-
cal groups. Each surface can then be further modified with target-
ing ligands or imaging agents. Such modifications in Janus particles
make them into bi- or multifunctional carriers [90], although it can
be challenging to adjust the properties of one hemisphere without
disturbing the other. There are a few ways of overcoming this
issue, including transiently masking one side of the particle while
modifying the other, or the micro-contact printing. These strate-
gies are described in more detail elsewhere [90].
Janus particles can be synthesized by combining two polymers
of distinct affinity for water, for example PLGA and polycaprolac-
tone (PCL) [91]. The combination of two different polymers allows
loading of hydrophilic and hydrophobic drugs, which will dis-
tribute unevenly in PLGA and PCL, which was shown by Li et al.
[91]. In their work, they used a hydrophilic fluorescent dye, Rho-
damine B, to stain Janus particles and they observed that the dye
mainly stains PLGA, implying that Rhodamine B can selectively
spread in different part of Janus particles. Furthermore, PLGA and
PCL show distinct degradation rates, which gives the possibility
for the delivery and controlled release of loaded drugs [91].
Another application of Janus particles includes the combination
of drug delivery and imaging. Janus PLGA microspheres were syn-
thesized with the magnetic Fe3O4 nanoparticles and the
fluorescent-labeled drug EuLa3(Bim)12, resulting in microspheres
which simultaneously had magnetic and fluorescent properties
[92]. The EuLa3(Bim)12 and Fe3O4 particles were evenly dis-
tributed in separate spheres and Janus microspheres exhibited bet-
ter fluorescent performance when compared to PLGA/EuLa3(Bim)
12/Fe3O4 composite microspheres [92].6. Therapeutic agents
6.1. Towards a perfect drug carrier
Particle size is a key parameter, which affects systemic distribu-
tion, cellular availability, uptake, and circulation lifetime [93]. For
example, the solvent evaporation method gives low control over
particle size distribution, while the spray-drying method requires
a high temperature, which can destroy the polymer structure and
damage the encapsulated cargo. The diameter of the particle can
easily be affected by cargo, polymer concentration or energy input
[37]. Extensive research has been carried over the past several
years to overcome the limitations of the current systems as
described in this review. One of the recent approaches to improve
drug encapsulation and controlled release is the use of a continu-
ous microfluidic FF method [94]. Xu et al. used this approach for
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and hydrophobic Tamoxifen in PLGA nanoparticles [94]. Here, they
used a partially water-miscible mixture as a precursor for drug/
polymer solution for nanoparticles nucleation, followed by the
extrusion of the solvent solution to an aqueous medium. The group
fabricated uniform PLGA nanoparticles with extremely high encap-
sulation efficiencies, as high as 88%, and longer sustained release
[94].
Another important factor, next to the well-defined size and size
distribution of particles, is the generation of drug carriers that can
encapsulate two or more drugs, for release in a controlled manner.
Controlled release of therapeutic drugs has a number of benefits
for therapy: it eliminates the need for repetitive dosing to support
the therapeutic effects, it provides better regulation and control
over the drug release rate, it protects active drugs from degrada-
tion and loss of therapeutic activity prior to delivery and it reduces
variability in drug-blood plasma concentrations which could lead
to toxicity issues [95]. In recent years, controlled drug delivery syn-
thesis and the polymers used in these systems have become much
more sophisticated, with the ability to do more than simply extend
the effective release period for a particular drug. One can trigger
the drug release by using stimuli responsive materials. Such mate-
rials can be sensitive to light, pH, temperature changes [76] or
other physicochemical stimuli, like glucose concentration [96].
6.2. Sustained release
The goal of many of the original controlled-release systems was
to achieve a delivery profile that would yield a consistently high
blood level of the drug over a long period of time. With traditional
tablets or injections, the drug level in the blood rises after each
administration of the drug and then decreases until the next
administration [97]. This level of the agent in the blood must
remain between a maximum value, which may represent a toxic
level, and a minimum value, below which the drug is no longer
effective. However, the actual drug levels will fluctuate widely
between these boundaries [97]. In controlled drug delivery sys-
tems designed for long-term administration, the drug level in the
blood remains constant, between the desired maximum and min-
imum, for an extended period of time. Depending on the synthesis
and the application, this time may vary between 24 h (Procardia
XL, Pfizer Inc., USA) to 1 month (Lupron Depot, AbbVie Inc., USA).
In recent years, controlled drug delivery synthesis and the poly-
mers used in these systems have become much more sophisti-
cated, with the ability to do more than simply extend the
effective release period for a particular drug. For example, current
controlled-release systems can respond to changes in the biologi-
cal environment and deliver—or cease to deliver—drugs based on
these changes. The common release mechanisms for PLGA particles
are usually the diffusion of the drug, solvent penetration/device
swelling, and degradation of the polymer matrix. A combination
of these mechanisms can also take place at different time points
[95].
Similar to the encapsulation of drugs, the release characteristics
of polymeric particles can be tuned for specific applications by the
synthesis method. The release of encapsulated drug depends on
various properties of the particles, e.g. the size of particles and
amount of loaded drug [15]. Typical PLGA release profiles consist
of an initial burst phase, induction period, slow release phase,
and final release phase. In the initial burst phase, around 30% of
the entrapped agent can be released within a few days, which
can hinder more specific control of release rates [15]. Such issues
can be solved by adjusting the polymer ratio, particle size, drug
content or the addition of coating to particles. Larger particles have
a smaller initial burst and longer sustained release when compared
to smaller particles [23]. When it comes to the amount of drug, thehigher the drug loading the higher the burst and faster the release
rate [23]. Blanco et al. developed PLGA nanoparticles designed for
protein delivery for extended period of time using a modified dou-
ble emulsion technique, and showed that the size of nanoparticles
and the protein encapsulation efficiency together with release rate
can be modulated by adjusting the synthesis conditions [98]. They
used PLGA copolymers with free terminal carboxyl groups for par-
ticle synthesis, which resulted in improved protein encapsulation
efficiency and decreased protein release rate [98].
There are three primary mechanisms by which active agents
can be released from a delivery system: diffusion, degradation,
and swelling followed by diffusion [15]. Drug release from PLGA
can be controlled by the degradation rate of the PLGA copolymer.
This can be achieved by the use of different molar ratios of the lac-
tic and glycolic acids in the polymer chain, molecular weight of the
polymer, and the degree of polymer crystallinity [94]. For a short-
term release (1 month) an amorphous polymer with higher
hydrophilicity is suitable, while for long-term release (1–6
months) an amorphous polymer with high molecular weight is rec-
ommended. Release longer than 6 months typically requires poly-
mer with a high degree of crystallinity [15]. Additionally, for the
delivery of drugs or other agents, the chemical properties of encap-
sulated compoundmust be taken into account; Siegel et al. showed
that the type of drug can influence the release and degradation rate
of PLGA polymer [99]. They compared the rate of drug release
through the degradation of 50:50 PLGA pellets for six different
drugs: thiothixene, haloperidol, hydrochlorothiozide, corticos-
terone, ibuprofen, and aspirin. The authors used identical polymer
matrices and drug loading, but the rate of polymer degradation and
drug release still varied significantly between drugs, ranging from
13 days (aspirin) up to 38 days (haloperidol) Thus, the authors con-
cluded that design of biodegradable polymeric drug carriers with
high drug cargo must account for the effect of the drug on polymer
degradation and drug release rate [99].6.3. Targeted delivery
Targeted drug delivery aims to accumulate drug at the site of
interest and could significantly lower side effects. Targeting the
region of interest, e.g. tumors and organs, by the modification of
the particle surface leads to an increase in selective cellular binding
and particle internalization via receptor-mediated endocytosis [4].
Functionalization of particles with ligands directed against surface
receptors of different cells can enhance the targeting of the
immune system [4]. Sharma et al. described different targeting
approaches in more details. Here, we give a few examples on the
modifications of particles for targeting application.
A major advantage of PLGA particles is that their surface can be
easily modified by the addition of targeting agents. A great number
of ligands have been evaluated to functionalize particles, including
peptides or proteins e.g. antibodies or lectins, glycoproteins,
polysaccharides, and glycolipids [100] to target various tissues,
for example brain, liver or tumors [101,102]. Typically, as shown
in several studies [103,104], targeting ligands are conjugated at
the particle surface through a PEG-linker. PLGA particles can be
also coated with surfactants to enhance the targeting, e.g. polysor-
bate 80-coated nanoparticles were reported to cross the blood-
brain barrier by mimicking the low density lipoproteins (LDL),
enabling them to connect with the LDL receptor and being taken
up by brain endothelial cells [105]. Another targeting approach
involves developing biomimetic particles, where particle core is
coated with the cell membranes, e.g. PLGA-indocyanine green par-
ticles were coated with cancer cell membrane, which resulted in a
better adhesion of particles to cancer cells and accumulation in a
tumor [106].
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which plasmacytoid dendritic cell (pDC) receptors can be used to
deliver antigens for antigen (cross-) presentation [107]. They
encapsulated peptide antigens together with the Toll-like receptor
7 agonist R848 in PLGA nanoparticles, which was followed by coat-
ing particles with PEG and streptavidin, and coupling specific
biotinylated antibodies, such as anti-DEC-205 or anti-CD32. The
results showed that targeting nanoparticles to pDCs improved
uptake, processing, and (cross-) presentation of encapsulated anti-
gen to both CD4+ and CD8+ T cells. Other studies also showed
enhanced immune response, when the antigens and adjuvants
were delivered to DCs via nanoparticles [108,109].
Cheng et al. studied the functionalized PLGA-PEG nanoparticles
for in vivo targeted drug delivery to prostate tumors. Here, PLGA-b-
PEG copolymer was synthesized by the conjugation of amino-
terminated-PEG to carboxy-terminated PLGA. They first synthe-
sized drug-loaded nanoparticles via nanoprecipitation technique.
These nanoparticles with desirable size and drug loading were
then conjugated to the specific aptamer for targeting. The final
results demonstrated enhanced nanoparticle delivery to prostate
tumors as compared to non-targeted nanoparticles [30].7. Theranostic agents
Theranostics is an emerging field which combines diagnostics
and therapeutics into multifunction nanoparticle systems [110].
Drug delivery and cell fate can be monitored using noninvasive
imaging techniques in order to optimize the route of delivery,
migration, proliferation, localization, and other factors. A number
of imaging modalities can be used for in vivo imaging, such as
MRI and ultrasound or fluorescent imaging [111]. The performance
of multimodal imaging can be improved by the intelligent design
of contrast agents to label cells. PLGA particles can be modified
for the use in diagnostic and therapeutic imaging by the addition
of imaging agents during the particle synthesis. PLGA particles
can be modified with the addition of different compounds, includ-
ing MRI contrast agents, fluorescent dyes, quantum dots, super-
paramagnetic iron oxides (SPIO) or radiotracers such as
technetium-99m [112–117].
There are several studies focusing on the development on PLGA
particles for MRI [118–120], for example, an amphiphilic Gd(III)
complex-loaded PLGA nanoparticles were formulated to provide
highly sensitive MRI contrast for imaging guided drug delivery
applications [121]. Our group demonstrated perfluorocarbon
(PFC)-loaded PLGA particles, which are prepared with the single
emulsion solvent evaporation method and can be used as imaging
agents for 19F MRI [122–126]. These particles can be customized
for multimodal imaging by the addition of fluorescent dye or radi-
oligand and also modified in terms of the particle diameter, and the
type and amount of the encapsulated PFC [123,127]. The PFC-
loaded PLGA particles were studied for in vivo imaging using both
19F MRI and fluorescence, after the injection of particles or previ-
ously particle-labeled dendritic cells (DC) in mice [123]. Addition-
ally, these particles can be used to encapsulate proteins or
peptides, making them an interesting candidate for a theranostic
agent. Alternatively, PLGA particles have also been loaded with
other imaging agents, most often with fluorescent dyes (e.g.
[128]), or MRI contrast agents as described previously.
In another study, anti-nucleolin-targeted magnetic PLGA
nanoparticles loaded with doxorubicin were developed to enhance
targeted cancer imaging and therapy [129]. SPIO/doxorubicin PLGA
nanoparticles were synthesized using modified multiple emulsion
solvent evaporation method and targeted with AS1411 aptamer
(Apt) against murine C26 coon carcinoma cells. Obtained particles
had doxorubicin loading of 3.0% and SPIO loading of 16%. As shownin the study, Apt conjugation to nanoparticles enhanced the cellu-
lar uptake of doxorubicin in C26 cancer cells. Apt-nanoparticles
enhanced both the cytotoxicity effect of doxorubicin and the con-
trast of MR images in tumor site [129].
Wang et al. combined imaging and therapeutic application by
synthesizing drug-encapsulating multifunctional nanoparticles
for photoacoustic and fluorescent imaging [105]. Here, particles
were prepared using double-emulsion solvent-evaporation
method, with silica-coated gold nanoparticles loaded into the par-
ticle core, and the hydrophobic Paclitaxel (drug loading efficiency
at 78.5%) and fluorescent dye encapsulation into the PLGA shell.
Gold nanoparticles were used due to their high optical absorption
and good photoacoustic signal. Synthesized nanoparticles were
then loaded into cancer cells and exposed to laser pulses. The
results show the decrease in cell viability due to the vaporization
of the particles in and around the cells [105]. Furthermore, the
studies in the phantoms and in vitro showed strong photoacoustic
signals, which suggests the possible application of these nanopar-
ticles as contrast agents for shallow tissue imaging. Overall, the
study by Wang et al. indicates that the combination of laser activa-
tion and drug release could lead to better therapeutic outcome
[105].
8. Conclusions and future perspective
Currently, the field of PLGA particles for medical applications is
one that involves chemists, biologists, and clinicians, as well as
academic and industrial groups. In the future, we expect new
design techniques and functionalization with stimuli-sensitive
‘‘smart” building blocks further broaden the use of PLGA and to
create efficient delivery systems, which will play a crucial role in
personalized medicine. Current extensive preclinical [130] studies
and ongoing clinical trials on biodegradable scaffolds
(NCT01753089 and NCT03066245) or monitoring cellular thera-
peutics (NCT02574377) using PLGA demonstrate the continuing
significance of this polymer [131], and show a great promise for
further improvements in therapeutic, diagnostic, and theranostic
agents. Multifunctional PLGA particles allow combining different
applications for better therapeutic outcome. Another approach is
to embed these multifunctional PLGA particles in various hydro-
gels or implants, which gives an interesting perspective for an
application in the biomedical field for monitoring the implants
and controlled release of active molecules.
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